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Ceramides are bioactive lipids that can promote splicing of apoptosis-related genes, 
including caspase 9 and BCL-x. A recent study demonstrated that expression of neutral 
sphingomyelinase (NSMase), an enzyme that hydrolyzes sphingomyelins to generate 
ceramide, is regulated by Group VIA phospholipase A2 (iPLA2β)-dependent mechanism 
during β-cell apoptosis.  This prompted us to hypothesize that iPLA2 is upstream of 
ceramide generation in the process regulating splicing of apoptotic genes. To test this, 
Jurkat T cells were treated with the selective inhibitor of iPLA2β, bromoenol lactone 
(BEL), RNA was isolated and converted to cDNA, and caspase 9 and BCL-x mRNA 
viii 
species were amplified using RT-PCR. Inhibition of iPLA2β activity with BEL caused a 
significant shift in splicing favoring variants encoding the anti-apoptotic forms of caspase 
9 (caspase 9b) and BCL-x (BCL-x(L)). This shift was consistent with previously reported 
effects of ceramide and suggested that iPLA2β regulates splicing of these pre-mRNAs. We 
next determined whether iPLA2β regulates splicing events during a biological response. 
Caspase-9 and BCL-x splice variants were compared in human and mouse islets, mouse 
islet cell lines, and in rat insulinoma (INS1) cells. 
 INS-1 insulinoma cells were treated with thapsigargin to induce ER stress, which 
can eventually lead to apoptosis.  Thapsigarin-treated INS-1 cells exhibited an increase in 
the ratio of BCL-x(s) (pro-apoptotic) to BCL-x(L) (anti-apoptotic) but BEL prevented this 
shift in splicing. Splicing data obtained from genetically modified rodent mice (iPLA2β 
knockouts and transgenics) also demonstrated the involvement of iPLA2β in alternative 
splicing. 
 Together, these observations indicate that iPLA2β plays an important role in the 
regulation of pre-mRNA splicing of key apoptotic factors. Our findings therefore suggest a 
novel role for iPLA2β in determining whether cells survive or undergo apoptosis. 
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CHAPTER 1: INTRODUCTION 
1.1 PHOSPHOLIPASES 
 
 Phospholipases are enzymes that hydrolyze phospholipids into fatty acids and other 
lipophilic substances (FIGURE 1A). There are four major classes, termed A, B, C and D 
distinguished by what type of reaction they catalyze (FIGURE 1B). Phospholipase A 
includes two groups of enzymes Phospholipase A1 (PLA1) and phospholipase A2 (PLA2). 
Phospholipase A1 cleaves the phospholipids at the SN-1 acyl position and phospholipase 
A2 cleaves the SN-2 acyl position Phospholipase B cleaves both SN-1 and SN-2 acyl 
chains and Phospholipase C cleaves before the phosphate, releasing diacylglycerol and a 
phosphate-containing head group. Phospholipase Cs play a central role in signal 
transduction, releasing the second messenger inositol triphosphate. 
Phospholipase D cleaves after the phosphate, releasing phosphatidic acid and an alcohol. 
 
 Phospholipase A2 (PLA2) enzymes are commonly found in mammalian tissues as 
well as insect and snake venom. This family of enzymes, as described earlier, cleaves the 
phospholipids at the SN-2 acyl chain to release unsaturated fatty acids and 
lysophospholipids. The common fatty acids released by this hydrolysis reaction are 
arachidonic acid (AA) and oleic acid (OA). Arachidonic acid can function as a messenger 
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and precursor of various bioactive pro-inflammatory compounds called eicosanoids 
(including prostaglandins, thromboxanes, lipoxins, and leukotrienes). These are known to  
 
 
mediate inflammation and signal transduction. Lysophospholipids, such as 
lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC), play important roles in 
cell signaling, phospholipid remodeling, and membrane perturbation (Six and Dennis., 
2000 and Kudo and Murakami.,2002). 
 
The PLA2 family can further be categorized into three classes based on their location and 
dependence on calcium levels.  
 Secreted phospholipase A2 (sPLA2) is the extracellular form of PLA2 that requires 
the presence of large (mM) amounts of calcium for its function. There have been 11 
isoforms identified so far and they have low molecular masses ranging from 14-17KDa. 
These enzymes play critical roles in several biological processes like eicosanoid 
generation, inflammation and host defense (Six et al 2000). 
 Cytosolic phospholipase A2 (cPLA2) is an intracellular form of the enzyme that is 
also calcium dependent for its function. This category of phospholipases is involved in 
cell signaling processes, such as inflammatory responses through the initiation of 
arachidonic acid metabolism. This family of enzymes shows a preference towards 
arachidonic acids compared to other fatty acids for hydrolysis at the SN-2 acyl positions. 
These are also known as Group IV PLA2s and there are six identified isoforms (cPLA2α, 
3 
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cPLA2β, cPLA2γ, cPLA2δ, cPLA2ε, cPLA2ζ). They are large proteins ranging from 61-
114KDa but are usually found at 85KDa. (Fuentes et al., 2002) 
 Calcium independent phospholipase A2 (iPLA2) is a Group VI, intracellular 
phospholipase A2 that is not dependent on calcium for its activity. It is a key player in 
glycerophospholipid and energy metabolism. There are six different isoforms all of which 
have masses ranging from 84 to 88KDa (Wilkins and Barbour, 2008).  
 Our focus is mainly going to be on iPLA2 and is discussed in further detail below. 
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FIGURE 1A: 
 
FIGURE 1B: 
 
REACTION CATALYZED BY PLA2 
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1.2 CALCIUM INDEPENDENT PHOSPHOLIPASE A2 (iPLA2) 
 
Group VI phospholipase A2 (iPLA2) is a calcium independent, intracellular enzyme that 
breaks down phospholipids to lysophospholipids and unsaturated fatty acids. It is the 
least characterized of all the PLA2s. It was first isolated and characterized from murine 
P388D1 macrophage like cells (Ackermann et al., 1994).  
This enzyme has the ability to hydrolyze both SN 1 and SN 2 fatty acids, but it shows a 
preference toward SN 2 fatty acids. (Ackermann et al.1994). In addition to its 
phospholipase activity, it also exhibits lysophopholipase and transacylase activities (Lio 
et al., 1998) and an acyl-CoA thioesterase activity (Carper et al., 2008). 
According to the current classification, iPLA2 products from different genes have been 
designated as the following: VIA or iPLA2β, VIB or iPLA2γ, VIC or iPLA2δ, VID or 
iPLA2ε, VIE or iPLA2ζ, and VIF or iPLA2η.  
 
 Several structural elements of the enzyme have been identified that help us gain a 
better understanding about the functional aspects of iPLA2 (FIGURE 2).The active site of 
the iPLA2 consists of the consensus lipase motif GXS465XG (Ser519in the human isoform) 
(Tang et al.,1997). iPLA2 also contains a string of eight successive ankyrin   repeats that 
are thought to be involved in protein-protein interactions (Larson et al.,1998) These 
repeats have also shown to be important for the enzymatic activity (Tang et al.,1997). 
These observations have led several groups to hypothesize that the ankyrin repeats play a 
role in the oligomerization of the protein. iPLA2 also consists of an ATP binding domain 
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(the enzyme requires the presence of ATP for optimal activity), a caspase 3 cleavage site, 
proline rich region, and a bipartite nuclear localization domain 
 
 iPLA2 pre-mRNA undergoes extensive alternative splicing that produces several 
mRNA transcripts that encode multiple isoforms with several distinct properties. There 
are two iPLA2 human isoforms-long and short. The human iPLA2 gene extends across a 
total of about 70 kilobases of DNA and contains 17 exons. (Ma et al.,1999). 
In 1998, two novel splice variants of iPLA2 were identified (Larsson et al.,1998) which 
were named ankyrin iPLA2-1 and ankyrin iPLA2-2. These sequences contain an 
additional exon which was then considered to be exon 10, which encodes an in-frame 
premature stop codon, as a result of which there is translational termination and 
expression of a truncated protein. 
Recent studies have demonstrated that the truncated iPLA2 protein is as a result of 
inclusion of exon 14 and not exon 10 (FIGURE 3). This protein has the N terminus 
ankyrin repeats but lacks the C- terminus lipase motif and hence is catalytically inactive. 
The protein has been identified to be about 45KD in size. The truncated protein product 
of ankyrin iPLA2 has been shown to act as a dominant negative of the full-length iPLA2 
(Larsson et al 1998). Studies from the same group have shown that the ankyrin iPLA2 
protein can negatively regulate the activity of the full length iPLA2 (Larsson et al 1998).   
Previous studies have shown that iPLA2 activity is cell cycle dependent (Manguikian et 
al,2004).  It was shown that the iPLA2 splice variant mRNA accumulates at the G2/M 
phase of the cell cycle where the iPLA2 activity is the highest. This poses the question of 
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the possibility of the downstream products of the iPLA2 reaction regulating the 
alternative splicing of the iPLA2 pre-mRNA and there by its activity. 
 
 There are several biological functions of iPLA2. The first is phospholipid 
remodeling (Balsnide 2002) which is a process, other than de novo synthesis, through 
which fatty acids can be incorporated into phospholipids.  
Regulation of phosphotidylcholine (PC) bio synthesis is also mediated by iPLA2  
(Anthony et al.,1999). iPLA2 leads to  the release of arachidonic acid that triggers certain 
mitogen activated protein kinases which activate proteins essential for cell division, by 
phosphorylating them. It is therefore involved in cell proliferation (Balboa et al., 2008, 
Roshak et al., 2000, Sanchez et al., 2002, Song et al., 2007). Several other studies have 
shown that iPLA2 is a key player in signal transduction (Maggi Jr. et al 2002, Atsumi et al 
1998, Jenkins et al 2009). 
 
 A key instrument used to perform all of these studies and gain a better 
understanding about the function of the enzyme is the iPLA2 selective inhibitor 
bromoenol lactone (BEL).  BEL is a suicide (irreversible) inhibitor that selectively targets 
iPLA2. It shows a thousand fold more selectivity for iPLA2 than cPLA2 and sPLA2. The 
S- enantiomer inhibits iPLA2β, while the R-enantiomer inhibits iPLA2γ (Jenkins et al., 
2002). The mode of action of BEL is thought to be via the acylation of the Serine residue 
present on the active site of the enzyme (Daniels et al.,1983 and Baek et al.,1990) 
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 BEL has been shown to inhibit the PLA2, transacylase and other catalytic activities 
associated with iPLA2 (Lio et al 1998, Jenkins et al 2006, Hazen et al 1991). This 
suggests that all these activities are likely mediated through the same active site.  
BEL has more recently been shown to inhibit serine proteases, magnesium dependent 
phosphotidate phosphohydrolase 1 and serine lipases. Despite this, BEL continues to 
remain one of the most widely used selective inhibitors of iPLA2 (Song et al.,2006). 
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FIGURE 2: 
 
 
STRUCTURAL ELEMENTS OF iPLA2 
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FIGURE 3:  
iPLA2 pre-mRNA SPLICING 
 
 
 
The iPLA2 pre-mRNA is alternatively spliced and generates the splice variant Ankyrin 
iPLA2. The splice variants are produced when alternative splicing incorporates exon 14 
(bold lines) which encodes an in-frame stop codon that generates an iPLA2 protein that 
retains the ankyrin repeats but not the lipase motif. This protein is catalytically inactive 
and functions as a dominant negative of the catalytically active full-length protein.
11 
1.3 INVOLVEMENT OF iPLA2β IN APOPTOSIS OF PANCREATIC β-CELLS 
 
The term apoptosis or programmed cell death was first coined in 1972 by John Kerr, 
Andrew Wilie and Alashair Currie. They observed different cell types undergo distinct 
morphological changes that eventually led to death differing significantly from necrosis. 
Apoptosis is characterized by a series of typical morphological features, such as shrinkage 
of the cell, membrane blebbing, fragmentation into membrane-bound apoptotic bodies and 
rapid phagocytosis by neighboring cells. Factors such as heat, radiation, nutrient 
deprivation, viral infection, hypoxia and increased intracellular calcium concentration 
drive cells toward apoptosis (Savil et al 1997).  
 
 Two important pathways through which apoptosis is mediated have been identified 
(Danial and Korsmeyer., 2004). They include intrinsic apoptotic pathway and the extrinsic 
pathway. The intrinsic pathway is mediated via the mitochondria and is characterized by 
permeabilisation of the mitochondria and release of cytochrome c into the cytoplasm. 
Cytochrome c then forms a multi-protein complex known as the ‘apoptosome’ and initiates 
activation of the caspase cascade through caspase 9 (Kroemer, Galluzzi, and Brenner., 
2007) 
The extrinsic apoptotic pathway takes place via the activation of cell death receptors on the 
plasma membrane such as tumor necrosis factor receptor 1 (TNFR1) and Fas/CD95. As 
ligands bind to these receptors, the death inducing signaling complex (DISC) is formed 
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leading to initiation of the caspase cascade through caspase 8 (Taylor, Cullen, and Martin., 
2008) 
 
 Recently a third mechanism through which apoptosis might take place has been 
identified; the ER stress pathway. The Endoplasmic Reticulum is critical for most cellular 
activities and cell survival. Conditions that interfere with ER function lead to the 
accumulation and aggregation of unfolded proteins. ER transmembrane receptors detect 
the onset of ER stress and initiate the unfolded protein response (UPR) to restore normal 
ER function. If the stress is prolonged, or the adaptive response fails, apoptosis takes place 
(Szegezdi et al., 2006). Several diseases including Alzheimer’s and Parkinson’s diseases, 
cancer, and obesity have been associated with ER stress induced apoptosis. (Hosoi and 
Ozawa, 2009). ER stress has also been shown to cause β-cell apoptosis eventually resulting 
in diabetes mellitus. Causes of both Type I and Type II diabetes have been attributed to 
loss of β-cell mass due to apoptosis. By nature of their secretory function, β-cells have very 
greatly developed ER which makes them highly sensitive to ER stress.  
 
 One of the tools used to study ER stress is the SERCA inhibitor Thapsigargin. 
Thapsigargin is non-competitive inhibitor of a class of enzymes known by the acronym 
SERCA, which stands for sarco / endoplasmic reticulum Ca2+ ATPase (Rogers et al 1995). 
Thapsigargin blocks the ability of the cell to pump calcium into the sarcoplasmic and 
endoplasmic reticula which causes these stores to become depleted. These conditions lead 
to ER stress. 
13 
13 
 
One of the first studies that provided evidence for the involvement of iPLA2β in ER stress 
induced apoptosis was performed by Polonsky (Zhou et al, 1998) and Kudo (Atsumi et al, 
2000). They showed that there was an induction of apoptosis in MIN-6 insulinoma cell 
when they were treated with thapsigargin and other SERCA inhibitors. This took place via 
a mechanism that involved the generation of arachadonic acid metabolites. They also noted 
that this mechanism was independent of intracellular calcium levels. This gave them 
reason to suspect the involvement of a PLA2 that has activity even in the absence of 
calcium. 
This was later confirmed in studies performed using U937 cell lines (human monocytes), 
where over expression of iPLA2β and not cPLA2 increased the occurrence of apoptosis in 
response to TNFα/cycloheximide. Immunoblot analyses revealed the presence of the full 
length iPLA2β band. (Atsumi et al, 2000). 
Subsequent studies from Ramanadham group have shown that INS-1 (rat insulinoma) cells 
over-expressing iPLA2β have higher incidence of apoptosis upon treatment with 
thapsigargin. This apoptosis was suppressed with BEL (selective inhibitor for iPLA2), 
providing further evidence that iPLA2β plays a role in ER stress induced apoptosis in yet 
another cell line (Ramanadham et al., 2004).  
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1.4. CASPASE 9 AND BCL-x 
Among the key players in apoptosis are caspase 9 and BCL-x, both of which are under the 
influence of the biologically active lipid, ceramide. 
Caspases, or cysteine-aspartic proteases, are a family of cysteine proteases, which play 
essential roles in apoptosis (programmed cell death), necrosis and inflammation. Caspase-9 
is an initiator caspase, encoded by the CASP9 gene. The human caspase 9 gene undergoes 
alternative splicing to produce two dominant-negative splice-variants designated caspase 
9a and caspase 9b. These splice-variants arise as an effect of inclusion or exclusion of the 
3, 4, 5, and 6 cassettes from the caspase 9 gene (Figure 4). The larger splice-variant (9a, 
with 3,4,5,6 cassette inclusion) is pro-apoptotic, while the smaller splice-variant (9b with 
3,4,5,6 cassette exclusion) is anti-apoptotic (Seol et al 1990). 
BCL-x , a member of the BCL2 family, also plays a role in apoptosis.  The proteins of the 
BCL 2 family govern mitochondrial outer membrane permeabilization (MOMP) and can 
be either pro-apoptotic (Bax, BAD, Bak and Bok among others) or anti-apoptotic 
(including BCL-2 proper, BCL-xL, and BCL-w) (Zamzami et al 1998).  
The anti-apoptotic factor, BCL-x(L) was shown to have a dominant negative splice-
variant, called BCL-x(s) (Minn et al., 1996). These splice variants arise as a consequence 
of alternative splicing of the BCL-x gene (FIGURE 5). There is a difference in the 
preference for the 5’ splice site in Exon two of this gene due to which pro-apoptotic variant 
(BCL-x(s)) lacks an exon in the coding region when compared to the anti-apoptotic variant 
(BCL-x(L)). 
15 
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FIGURE 4: 
ALTERNATIVE SPLCING OF HUMAN CASPASE 9 
 
 
(Adapted from Chalfant et al 2002) 
 
The human caspase 9 gene undergoes cassette splicing where inclusion of the 3.4.5.6 
cassette gives rise to the larger, pro-apoptotic splice variant, caspase 9a while its 
exclusion produces the smaller, anti-apoptotic splice variant, caspase 9b. 
16 
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FIGURE 5:  
ALTERNATIVE SPLICING OF HUMAN BCL-x 
 
 
 
(Adapted from Chalfant et al 2002) 
 
Based on the difference in the preference for the 5’splice site, two BCL-x splice variants 
arise; BCL-x(L) is the larger anti-apoptotic splice variant and BCL-x(s) is the smaller pro-
apoptotic splice variant. 
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 In 2002, Chalfant group showed that caspase 9 and BCL-x genes were under the 
influence of ceramide. They demonstrated that A 549 lung adenocarcenoma cells, when 
treated with short chain ceramide underwent alternative splicing to produce the  
pro-apoptotic splice variants of both genes and also went on to delineate the mechanism by 
which ceramide regulates alternative-splicing of these genes (Chalfant et al., 2002). 
According to this mechanism, ceramides activate protein phosphotases (like PP1) which 
dephsphorylate splicing proteins (such as SR proteins) and eventually leading to alternative 
splicing (Chalfant et al 2002). 
 
 Ceramides are a family of lipid molecules. A ceramide is composed of sphingosine 
and a fatty acid. Ceramides are found in high concentrations within the cell membrane of 
cells. They are one of the component lipids that make up sphingomyelin, one of the major 
lipids in the lipid bilayer.  Perhaps one of the most fascinating aspects of ceramide is that it 
can act as a signaling molecule.  
There are three major pathways of ceramide generation. The sphingomyelinase pathway 
uses an enzyme to breakdown sphingomyelin in the cell membrane and release ceramide. 
The de novo pathway creates ceramide from less complex molecules like palmitate. 
Ceramide generation can also occur through breakdown of complex sphingolipids that are 
ultimately broken down into sphingosine, which is then reused by reacylation to form 
ceramide. This latter pathway is termed the Salvage pathway (Kitatani et al 2008).  
Dr. Ramanadham’s group in 2004 demonstrated that iPLA2β leads to the accumulation of 
ceramides. They showed that INS-1 cells over expressing iPLA2β had greater levels of 
18 
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ceramides upon treatment with ER stress inducer thapsigargin, when compared to the cells 
transfected with vector alone. More importantly, they showed that these elevated levels can 
be dramatically suppressed with the iPLA2β inhibitor BEL. (Ramanadham et al 2004). 
They also pointed out that the generation of ceramides during ER stress takes place via the 
induction of Neutral Sphingomyelinase (NSMase) which breaks down sphingomyelins to 
release ceramides. Interestingly enough, they observed that BEL treatment not only 
suppressed ceramide levels, but also NSMase levels (Lei et al., 2008).  
This suggests that iPLA2β is upstream of NSMase and that the induction of NSMase 
during ER stress is iPLA2β dependent.  
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CHAPTER 2: HYPOTHESIS 
 
 Evidence from previous studies gives us reason to believe that iPLA2β plays a role 
in apoptosis and is upstream of ceramides.  We hypothesize that iPLA2β is involved cell 
apoptosis by modulating alternative splicing of BCL-x and Caspase 9 genes in a ceramide 
mediated manner. The ceramides generated trigger the alternative splicing events of BCL-x 
and Caspase 9 to favor the production of pro-apoptotic splice variants that play a 
significant role in cell death.  
20 
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CHAPTER 3: MATERIALS AND METHODS 
 
 3.1 CELL CULTURE AND TREATMENTS: Jurkat cells were cultured in 
modified RPMI-1640 medium (Cellgro), supplemented with 10% heat inactivated fetal calf 
serum(FCS) , 2mM L-glutamine (Gln), 100µg/mL penicillin and 100µg/mL streptomycin 
(P/S), at 5% CO2, 100% humidity and 37ºC. Jurkat cells were treated with 10µM BEL 
overnight. 
INS1 cells (rat insulinoma cell line) were cultured in RPMI 1640 media with 10%  heat 
inactivated FCS, 2mM L- Gln, 100 µg/mL each P/S, 10mM HEPES, 1mM sodium 
pyruvate, 11mM glucose and 50µM β-mercaptoethanol.  
Cells were treated with 10µM bromoenol lactone (BEL, selective iPLA2 inhibitor), 20µM 
C6 ceramide (16 hrs) and 10µM Thapsigargin (ER stress inducer) as indicated. 
Human Embryonic Kidney (HEK) cells used for the mini-gene experiments were 
maintained in modified DMEM (Cellgro) supplemented with 10% heat-inactivated FCS, 
2mM L-Gln, 100µg/mL each P/S, at 5% CO2, 100% humidity and 37ºC.  
  
3.2 MOUSE ISLETS: RNA samples from mouse islets were obtained from  
Dr. Ramanadham, Washington University, St. Louis, MO.  
All animal experiments were performed in accordance with IACUC regulations of 
WUSTL. Pancreas were harvested from 4-5 week old male mice and islets prepared as 
21 
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described (Lei, 2010). Islets were cultured in RPMI 1640 media with 10% FCS and P/S. 
Where indicated, islets were treated with 0.2mM thapsigargin. 
3.3 RT-PCR ANALYSIS:  RNA was isolated with Trizol-LS and was converted to cDNA 
with oligo dT primer using the Thermoscript cDNA kit. The cDNA was then amplified 
using the Accuprime Taq PCR kit and gene-specific primers (Table 1) at their respective 
annealing temperatures. 
The amplified samples were analyzed using 6% acrylamide gel electrophoresis at a 100 
volts with 0.5x TBE as the running buffer, followed by staining with sybr gold (a 1:10 
dilution of the solution made with the running buffer).  Images were collected with a 
Typhoon scanner and signals were quantified with Image Quant software. 
 
3.4 BCL-x MINIGENE: A Bcl-x minigene construct was obtained from  C. Chalfant 
(VCU). The minigene consists of exon 1, intron 1, exon 2, and portions of intron 2 and 
exon 3 (Massiello, 2003). The minigene was transfected into HEK cells using Fugene 6 
reagent. Transfected cells were treated as indicated and RNA was isolated and converted to 
cDNA with oligo dT primers. The resulting cDNA was then amplified by PCR with the 
Bcl-x minigene primers whose sequences are 5’ aaacttaagcttggtaccgag 3’ (forward) and 5’ 
ggagctggtggttgactttct 3’ (reverse) (Massiello, 2003). The amplified samples were analyzed 
by acrylamide gel electrophoresis. The amplified samples were analyzed by acrylamide gel 
electrophoresis, as described earlier. Images were collected with a Typhoon scanner and 
signals were quantified with Image Quant software. 
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3.5 IMMUNOBLOT ANALYSES: Cells were harvested, sonicated, and an aliquot (30-90 
μg) of lysate protein was analyzed by SDS-PAGE (10 or 15%), transferred onto 
nitrocellulose membrane and analyzed for the desired protein. The primary antibody used 
for Caspase 9 (1:800) was purchased from Assay designs. An HRP tagged anti-mouse 
secondary was used. The proteins were detected using Femto. 
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TABLE 1: 
PRIMER SEQUENCES USED 
Primer Sequence Annealing temperature
Human BCL-x Forward: 5’gaggcaggcgacgagtttgaa 3’ 
Reverse: 5’tgggagggtagagtggatggt 3’ 
58 ºC 
 
Rat BCL-x Forward: 5’ggagagcattcagtgatc 3’ 
Reverse: 5’ caatggtggctgaagaga 3’ 
48 ºC 
Mouse BCL-x Forward: 5’atccacaaaagtgtcccagc3’ 
Reverse: 5’ ccgtagagatccacaaaagtctc 3’
54 ºC 
 
Human Caspase 9 Forward: 5’gctcttcctttgttcatctcc 3’ 
Reverse: 5’catctggctcggggttactgc 3’ 
58 ºC 
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CHAPTER 4: RESULTS 
 
Previous studies have shown that ceramides regulate alternative splicing of caspase 9 and 
BCL-x (Chalfant et al2002). Studies have also correlated iPLA2 activity with ceramide 
production via the generation of unsaturated fatty acids that induce sphingomyelinase 
(Ramanadham et al 2004 and Lei et al 2008). These evidences raise a question about the 
potential involvement of iPLA2 in regulating alternative splicing of caspase 9 and BCLx. 
One of the first indications we received about the role of iPLA2β in alternative splicing, 
was from Jurkat T cells. These cells were treated with the iPLA2β inhibitor BEL overnight, 
RNA was isolated and converted to cDNA. The cDNA was then subjected to a PCR 
analysis with caspase 9 and BCL-x primers to amplify for their pro-apoptotic and anti-
apoptotic splice variants. We observed that there was a dramatic shift toward the anti-
apoptotic splice variants in both Caspase 9 and BCL-x upon treatment with BEL, when 
compared to those treated with vehicle (DMSO) alone. That is, inhibition of iPLA2β in 
these cells produced a shift in splicing of the Caspase 9 and BCL-x genes to their anti-
apoptotic forms. This gave us the reason to believe that iPLA2β is involved in the 
alternative splicing of Caspase 9 and BCL-x. (FIGURE 6) 
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4.1 REGULATION OF BCL-x SPLICING: 
We next wanted to apply our newly acquired knowledge to a system of a greater 
physiological relevance: ER stress induced apoptosis of the β-cell. As previously 
mentioned, it has been shown that thapsigargin-induced apoptosis in INS-1 cells, can be 
significantly suppressed by the iPLA2β inhibitor BEL (Ramanadham et all 2004).  
It was also shown that there is an increased accumulation of ceramides with thapsigargin 
treatment in cells that are over-expressing iPLA2β when compared to the cells transfected 
with vector alone (Ramanadham et al 2004). The Ramanadham group also demonstrated 
that this accumulation of ceramides could be blocked by inhibiting iPLA2β with BEL. 
Putting two and two together, we asked ourselves if iPLA2β is bringing about apoptosis in 
these cells by regulating alternative splicing of the apoptotic genes caspase 9 and  
BCL-x. 
 
 To test our hypothesis, we treated INS-1 cells with BEL and/or thapsigarigin, 
isolated RNA and subjected it to RT-PCR analysis of the BCL-x splice variants.  We 
observed that the ER stress inducer, thapsigargin shifts splicing toward the pro-apoptotic 
splice variant (BCL-x(s)), more importantly, this shift was prevented by the iPLA2β 
inhibitor BEL. We also noticed that BEL by itself had the ability to shift splicing to the 
anti-apoptotic form of BCL-x. (BCL-x(L)). Similar shifts in BCL-x splicing were observed 
in the human systems as well. While thapsigargin produced more of the pro-apoptotic 
BCL-x(s), inhibition of iPLA2β with BEL prior to thapsigargin treatment shifted splicing in 
the opposite direction; that is toward the anti-apoptotic BCL-x(L) 
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(FIGURE 7). These data strengthen our hypothesis about the involvement of iPLA2β in 
alternative splicing of BCL-x. While ER stress drives splicing toward pro-apoptotic BCL-
x(s), inhibition of iPLA2β drives splicing in the opposite direction; toward the anti-
apoptotic BCL-x(L). 
 
  Our study thus far has been focused on the chemical inhibition of iPLA2β 
with BEL. But, as mentioned previously, BEL also shows certain non-specific effects. It 
was hence essential for us to look at certain genetically modified rodent models to confirm 
the proposed role for iPLA2β in alternative splicing.  
RNA from iPLA2β knockout and transgenic mice islets was obtained from Dr. 
Ramanadham at Washington University, St.Louis MO. The islets were cultured in the 
presence or absence of thapsigargin.  
We converted the RNA to cDNA and subjected it to PCR analysis of mouse BCL-x and 
compared the ratios of the splice-variants with that of the wild type islets. In the wild type 
islets, thapsigargin shifts splicing toward the pro-apoptotic splice variant, BCL-x(s) as 
compared to the untreated cells that had very low levels of BCL-x(s). In the transgenic 
islets, there was a significant level of the pro-apoptotic signal even in the untreated 
samples. Conversely, in the iPLA2β knockouts, there was negligible amount of BCL-x(s) 
present even after treatment with thapsigargin (FIGURE 8). 
These observations illustrate that iPLA2β regulates alternative splicing of the BCL-x gene, 
toward the pro-apoptotic splice variant (BCL-x(s)) and knockdown of iPLA2β shifts 
splicing in the opposite direction.     
27 
27 
 
 
 Up until now, ER stress in cells was artificially induced using thapsigargin. This is 
not a fool proof phenomenon as there could be other non-specific targets of the drug. We 
hence decided to see if our observations hold true in systems that are naturally undergoing 
ER stress. One such system is the Akita mouse. Akita mice develop diabetes as a 
consequence of a single base pair substitution in the Ins2 gene, resulting in improper 
folding of pro-insulin which leads to protein aggregate-induced ER stress in the pancreatic 
islets ( Koizumi et al, 1997).   
 
 It was recently shown that thapsigargin accelerates apoptosis of Akita β-cells and 
that this is associated with increased iPLA2β expression (Lei et al, 2010). We thus wanted 
to see if BCL-x splicing correlates with the above data. 
RT-PCR analysis of RNA from Akita mice showed an increase in ratio of BCL-x(s)  
(pro-) to BCL-x(L) (anti-apoptotic) in the Akita islets when compared to the wild type 
(FIGURE 9). This observation may be attributed to the fact that there are elevated levels of  
iPLA2β expression in the Akita islets, compared to the wild type (Lei et al 2009), which 
subsequently leads to a shift toward the pro-apoptotic splice variant of BCL-x thereby 
increasing the ratio of BCL-x(s) (pro) to BCL-x(L) (anti). 
 
 We also developed a transfection protocol in the HEK cells for the BCL-x mini-
gene that was obtained from Dr. Chalfant. This mini-gene is constructed such that it 
mimics the endogenous BCL-x. The mini-gene like the endogenous BCL-x also shows a 
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difference in the 5’ splice site so that two splice variants that are comparable to the larger 
BCL-x(L) which is anti-apoptotic and the smaller BCL-x(s) which is pro-apoptotic.  
 
The PCR products of the mini-gene splice variants are 751 bp (x(L)) and 565 bp (x(s)) 
 (Massiello et al, 2004). 
On performing an RT PCR analysis on the RNA isolated from HEK cells transfected with 
the mini-gene, we detected a shift in splicing toward the larger (anti-apoptotic) splice 
variant in the BEL (iPLA2β inhibitor) treated sample (FIGURE 10). This observation now 
gives us the tool to direct our future studies toward the mechanistic aspects of the splicing 
events of BCL-x. 
 
4.2 REGULATION OF CASPASE 9 SPLICING: 
iPLA2β also seems to be regulating the splicing events of caspase 9. In the human system, 
a simple RT PCR analysis of caspase 9 message from RNA isolated from human islets 
revealed a shift in splicing toward caspase 9a with thapsigargin treatment. This shift was 
blocked by the iPLA2β inhibitor BEL (FIGURE 11). Therefore, there is an increase in the 
pro-apoptotic message of Caspase 9 in human islets under ER stress conditions and 
inhibition of iPLA2β in such conditions blocks this effect and brings down the ratio of pro-
apoptotic (9a) to anti-apoptotic (9b).  
Although we do not have RT PCR tools to quantify for caspase 9 messages in the rat 
system, we were able to perform western analysis of the caspase 9 protein in INS-1 cells. 
The caspase 9a protein is expected to be around 47kDa and the 9b around 37KDa. We 
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observed a dramatic increase in the pro-apoptotic caspase 9a protein in iPLA2β over-
expressing cells when treated with the ER stress inducer thapsigargin compared to the cells 
that were transfected with vector alone. The ratio of caspase 9a/9b protein was about four 
fold higher than in the cells over expressing iPLA2β (FIGURE 9).  
 
Hence far our data suggest that iPLA2β is playing a vital role in the alternative splicing of 
caspase 9 and BCL-x. Over expression of iPLA2β augments the pro-apoptotic splice 
variants of both caspase 9 (9a) and BCL-x (xL) in both the human and rodent models and 
its inhibition shifts the splicing events in the opposite direction. Inhibition of iPLA2 in ER 
stress conditions protects the cells by causing a shift in splicing of caspase 9 and BCL-x 
toward their anti-apoptotic forms. This and evidences from previously published work 
(Ramanadham et al, 2004) together suggest that cell death during ER stress conditions may 
be mediated via iPLA2β.  
 
 
4.3. ALTERNATIVE SPLICING IS MEDIATED THROUGH CERAMIDE:  
One of the important aspects of our hypothesis is that iPLA2β is influencing alternative 
splicing through the induction of ceramides. As mentioned above, the Ramanadham lab 
has shown that there are elevated levels of ceramide in cells over-expressing iPLA2β and 
that these levels can be significantly suppressed using the iPLA2β inhibitor, BEL 
(Ramanadham et al 2004). Ceramides have also been implicated to shift splicing events of 
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caspase 9 and BCL-x in A549 lung carcinoma cells by the Chalfant group (Chalfant et al, 
2002).  
Our goal was to see if ceramide treatment of INS-1 cells can produce splicing results 
similar to what was observed by the Chalfant lab. RT PCR analysis of RNA extracted from 
INS-1 cells treated with ceramide produced a increase in ratio of BCL-x(s)/BCL-x(L) 
when compared to the vehicle control (FIGURE 12). That is, there was more of the pro-
apoptotic BCL-x(s) signal upon treatment with ceramide.  
Both thapsigargin and ceramide seem to be causing a similar effect on the splicing of BCL-
x; while one is upstream of iPLA2β, the other is downstream, respectively. 
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FIGURE 6: 
BEL MODULATES SPLICING OF CASPASE 9 AND BCL-x IN 
JURKAT T CELLS 
 
 
n=1 
Electrophoretic analysis of amplified m-RNA from cells incubated with and without the 
iPLA2β inhibitor BEL. Inhibition of iPLA2β shifts splicing of caspase 9 and BCL-x 
towards their anti-apoptotic forms. 
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FIGURE 7: 
iPLA2β INHIBITOR SHIFTS SPLICING TOWARD ANTI-APOPTOTIC 
BCL-x(L) IN INS-1 CELLS AND HUMAN ISLETS 
 
 
n=1 
Thapsigargin (ER stress inducer )shifts splicing towards the pro-apoptotic BCL-x(s), but 
BEL (selective inhibitor of iPLA2β) prevents this effect and shifts splicing in favor of 
anti-apoptotic BCL-x(L). Left: INS-1 cells; Right: Human islets. 
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FIGURE 8: 
MODULATION OF BCL-x SPLICING IN GENETICALLY 
ALTERED MICE 
 
n=1 
Islets were cultured in the presence or absence of thapsigargin (ER stress inducer). In wild type 
(WT) islets, and very little BCL-x(s) is present in untreated cells but the thapsigargin shifts 
splicing in favor of this pro-apoptotic variant. In contrast, BCL-x(s) is present in transgenic (TG, 
over expressing iPLA2β) islets, even in the absence of thapsigargin treatment. Conversely, very 
little BCL-x(s) is present in iPLA2β-/- (KO)islets even after thapsigargin treatment.
34 
34 
 
 
FIGURE 9: 
BCL-x SPLICING IN AKITA MOUSE ISLETS 
 
 
n=1 
Akita mice develop spontaneous ER stress and hyperglycemia/ diabetes due to β-cell 
apoptosis. It was recently shown that thapsigargin accelerates apoptosis of Akita β-cells 
and that this is associated with increased iPLA2β expression. Correspondingly, the ratio 
of BCL-x(s) to BCL-x(L) is elevated in islets from Akita mice. 
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FIGURE 10: 
iPLA2β INHIBITOR SHIFTS SPLICING OF BCL-x MINIGENE 
 
 
 BCl-x minigene in HEK cells. BEL (selective iPLA2β inhibitor) shifts splicing to favor 
the anti-apoptotic BCL-x(L). 
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FIGURE 11: 
 A. 
iPLA2β INHIBITOR, BEL, SHIFTS SPLICING TOWARD 
ANTI-APOPTOTIC CASPASE 9b IN HUMAN ISLETS 
 
Thapsigargin (ER stress inducer) shifts splicing towards pro-apoptotic caspase 9a, but 
BEL (iPLA2β selective inhibitor) prevents this effect. 
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B. 
OVER-EXPRESSION OF iPLA2β INCREASES THE ABUNDANCE OF PRO-
APOPTOTIC CASPASE 9a PROTEIN IN INS-1 CELLS 
 
 Induction of ER stress in iPLA2β over-expressing INS-1 cells produces an increase in 
amount of caspase 9a protein when compared to induction of ER stress in INS-1 cells 
transfected with the vector alone. 
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FIGURE 12: 
CERAMIDE BRINGS ABOUT A SHIFT IN SPLICING TO FAVOR THE 
PRO-APOPTOTIC BCL-x(s) 
 
 
 
RT-PCR analysis showing that treatment of INS-1 cells with C-6 ceramide increases the 
pro-apoptotic BCL-x(s) message when compare to cells treated with the vector alone.   
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CHAPTER 5: DISCUSSION 
 
 Over the years many groups have put forward evidences that point toward the 
involvement of iPLA2β in apoptosis. 
We hypothesized that iPLA2β induces pre-mRNA splicing events of caspase 9 and BCLx 
in favor of their pro-apoptotic forms thus playing a critical role in apoptosis. Our 
hypothesis was based on studies that have illustrated that over-expression of iPLA2β 
increases the incidence of apoptosis accompanied with a marked increase in the 
endogenous levels of ceramides. The Ramanadham lab has previously shown (Lei et al 
2008) that accumulation of ceramides during ER stress takes place through the activation 
of iPLA2β that drives the expression of neutral sphingomyelinase (NSMase); the enzyme 
that hydrolyses sphingomyelins to ceramides. Ceramides in turn have been shown to 
modulate the splicing events of caspase9 and BCL-x by the Chalfant group (Chalfant et al 
2002).  
These observations have made it important for us to focus our attention toward the 
possibility of iPLA2β playing a direct role in the alternative splicing of caspase 9 and BCL-
x. 
 To test our hypothesis we made use of both pharmacological and genetic tools to 
alter the activity of iPLA2β, followed by a comparison of the relative expression of the pro-
apoptotic to anti-apoptotic splice variants of caspase 9 and BCL-x in INS-1 cells, mouse 
and human islets.  
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On comparing the BCL-x splice variants, we were able to see that inhibition of 
iPLA2β chemically (with its specific inhibitor BEL) or genetically (by a complete 
knockout of the enzyme) produce a shift in splicing of the BCL-x gene toward the anti-
apoptotic splice variant (figures 7 and 8 respectively) . Conversely, we observed more of 
the pro-apoptotic splice variant in the iPLA2β over expressers and in the iPLA2β transgenic 
mice islets (figure 7 and 8 respectively).  
We made similar observations for caspase 9 at the RNA level (figure 11A) in human islets 
and at the protein level (figure 11B) in the INS-1 cells.  
 
Taken together, our data point toward the prospect of iPLA2β regulating the 
alternative splicing of caspase 9 and BCL-x. Increased iPLA2β levels in the system drive 
splicing toward the pro-apoptotic splice variants while inhibition of the enzyme produce a 
shift to favor the anti-apoptotic forms. 
 
We have also acquired data that suggest the involvement of iPLA2β in ER stress 
induced apoptosis. Thapsigargin (ER stress inducer) treated INS-1 cells produced more of 
the pro-apoptotic splice variant of BCL-x (BCL-x(s)) (figure 7). This observation was 
consistent with the one made by the Ramanadham lab where thapsigargin treatment 
induces apoptosis in INS-1 cells (Ramanadham et al 2004). But a more intriguing 
observation was that we could shift this splicing toward the anti-apoptotic form by 
treatment with BEL prior to thapsigargin treatment, which again can be correlated to the 
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inhibition of apoptosis of INS-1 cells under ER stress with BEL treatment, previously 
observed by Ramanadham group.  
 
Another piece of the puzzle is the information obtained from the Akita mice (figure 
9). Previous studies have shown that these mice develop diabetes as a result of ER stress 
mediated apoptosis. The islets from these mice show elevated levels of iPLA2β expression 
(Lei et al 2009). Consistent with these data was an increase in ratio of the BCL-x(s)/BCL-
x(L) (pro/anti) in the Akita islets.  Thus, data from the Akita mice also suggest that under 
ER stress conditions, iPLA2β is regulating the alternative splicing of BCL-x and caspase 9.      
 
 Our latest addition to these studies is the BCL-x mini-gene transfection which we 
have currently developed in the HEK cells (figure 10). The fact that inhibition of iPLA2β 
shifts splicing of this exogenously expressed gene also, gives us the ability in the future to 
pin point the molecular mechanism by which this alternative splicing is taking place.   
 
 Since we postulated that iPLA2β was bringing about alternative splicing through 
ceramide, it was imminent for us to see what happens to splicing upon treatment with 
ceramide. We have most recently performed experiments that provide evidence for the 
involvement of ceramide in the alternative splicing of BCL-x. Cells treated with C-6 
ceramide clearly showed a marked increase in the pro-apoptotic splice variant of BCL-x 
(figure 12). 
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 We hence believe that iPLA2β participates in the regulation of both caspase 9 and 
BCLx pre-mRNA splicing. This seems to be true even in the cases of ER stress mediated 
apoptosis. The most probable means by which this is taking place is through the increase in 
the endogenous ceramide levels mediated via the induction of NSMase by iPLA2β. Based 
on these inferences, we put forward a model for a possible pathway through which 
alternative splicing takes place. According to this model, an initial insult (pro-
inflammatory cytokines, ER stress, etc) activates the mitochondrial apoptotic pathway 
resulting in caspase-3 activation and processing of iPLA2β.  Caspase-3-cleaved iPLA2β 
translocates to the nucleus where it increases neutral sphingomyelinase (NSMase) 
message.  A nuclear pool of NSMase protein generates ceramides, which activate PP1, 
resulting in dephosphorylation of splicing proteins and hence altering the splicing events of 
caspase-9 and BCL-x pre-mRNAs to increase expression of pro-apoptotic caspase-9a and 
reduce expression of anti-apoptotic Bcl-x(L) (Figure 13).   
Our efforts in the future will be directed towards the investigation of this theory.  
 
 These findings are of significant importance in respect of addressing diabetes 
which has been shown to be a result of loss of β-cell mass due to apoptosis (Butler et al 
2003). ER stress mediated apoptosis is gaining a lot of attention in the β-cell world and 
iPLA2β, as shown above, seems to be an integral part of this mechanism via the regulation 
of pre-mRNA splicing. Our studies will therefore add to the ongoing efforts toward the 
discovery of novel therapeutic targets for diabetes. 
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 Taken together, our work suggests a novel function for iPLA2 that is independent 
of its effects on lipid metabolism; that is regulation of alternative splicing and involvement 
in cell apoptosis.  
 
 Our future experiments to strengthen the already existing evidence are mechanistic 
studies using the mini gene and siRNA studies against NSMase and iPLA2β. Additionally, 
we would like to focus our attention on acquiring better tools to look at caspase 9 in rodent 
models. We also intend on delineating the events that are leading to the generation of 
ceramides downstream of iPLA2β. 
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FIGURE13: PROPOSED MODEL 
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The initial insult (pro-inflammatory cytokines, ER stress, etc) activates the 
mitochondrial apoptotic pathway resulting in caspase 3 activation and processing of 
iPLA2β. Caspase-3-cleaved iPLA2β translocates to the nucleus where it increases neutral 
sphingo myelinase (NSMase) message. A nuclear pool of NSMase protein generates 
ceramides, which activate PP1, resulting in dephosphorylation of splicing proteins and 
altering splicing of caspase 9 and BCL-x pre-mRNAs to an increase in pro-apoptotic 
caspase 9a and a decrease in anti-apoptotic BCL-x(L). 
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